Search results for "infarct"

showing 10 items of 1223 documents

Prognostic Value of Initial Left Ventricular Remodeling in Patients With Reperfused STEMI

2019

Abstract Objectives This study sought to establish the best definition of left ventricular adverse remodeling (LVAR) to predict outcomes and determine whether its assessment adds prognostic information to that obtained by early cardiac magnetic resonance (CMR). Background LVAR, usually defined as an increase in left ventricular end-diastolic volume (LVEDV) is the main cause of heart failure after an ST-segment elevated myocardial infarction; however, the role of assessment of LVAR in predicting cardiovascular events remains controversial. Methods Patients with ST-segment elevated myocardial infarction who received percutaneous coronary intervention within 6 h of symptom onset were included …

MaleLeft ventricular ejection fractionTime FactorsDatabases FactualCardiac magnetic resonancemedicine.medical_treatment030204 cardiovascular system & hematologyLeft ventricular end-diastolic volumeInfarct sizeVentricular Function Left030218 nuclear medicine & medical imaging0302 clinical medicineRisk FactorsCause of DeathClinical endpointMyocardial infarctionRegistriesRandomized Controlled Trials as TopicEjection fractionVentricular RemodelingHazard ratioMiddle AgedMicrovascular obstructionPrognosisMagnetic Resonance ImagingHospitalizationTreatment OutcomeCardiologyEnd-diastolic volumeFemaleCardiology and Cardiovascular Medicinemedicine.medical_specialtyLeft ventricular end-systolic volume03 medical and health sciencesPercutaneous Coronary InterventionPredictive Value of TestsInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingVentricular remodelingAgedHeart Failurebusiness.industryLeft ventricular remodelingPercutaneous coronary interventionArrhythmias CardiacStroke VolumeRecovery of Functionmedicine.diseaseST-segment elevation myocardial infarctionHeart failureST Elevation Myocardial Infarctionbusiness
researchProduct

Texture analysis of cardiac cine magnetic resonance imaging to detect nonviable segments in patients with chronic myocardial infarction.

2017

[EN] Purpose: To investigate the ability of texture analysis to differentiate between infarcted nonviable, viable, and remote segments on cardiac cine magnetic resonance imaging (MRI). Methods: This retrospective study included 50 patients suffering chronic myocardial infarction. The data were randomly split into training (30 patients) and testing (20 patients) sets. The left ventricular myocardium was segmented according to the 17-segment model in both cine and late gadolinium enhancement (LGE) MRI. Infarcted myocardium regions were identified on LGE in short-axis views. Nonviable segments were identified as those showing LGE 50%, and viable segments those showing 0 < LGE < 50% transmural …

MaleLocal binary patternsMyocardial InfarctionMagnetic Resonance Imaging Cine030204 cardiovascular system & hematology030218 nuclear medicine & medical imagingTECNOLOGIA ELECTRONICA03 medical and health sciencesMagnetic resonance imaging0302 clinical medicineDiagnosisMachine learningmedicineImage Processing Computer-AssistedLate gadolinium enhancementHumansIn patientcardiovascular diseasesAnalysis methodRetrospective StudiesChronic myocardial infarctionTissue SurvivalReceiver operating characteristicmedicine.diagnostic_testbusiness.industryMagnetic resonance imagingHeartGeneral MedicineMiddle AgedClassificationChronic Diseasecardiovascular systemLeft ventricular myocardiumFemaleNuclear medicinebusinessMedical physics
researchProduct

Observed and relative survival and 5-year outcomes of patients discharged after acute myocardial infarction: the nationwide AMI-PL database.

2020

Background: Long‑term follow‑up data from a large Polish acute myocardial infarction (AMI‑PL) database are still unavailable. Aims: This study aimed to assess the 5‑year outcomes of patients discharged after hospitalization for AMI in Poland in relation to age. Methods: The studywas based on the nationwide AMI‑PL registry including data on the management and long‑term outcomes of all patients admitted to hospitals with AMI (codes I21–I22 according to the International Classification of Diseases and Related Health Problems, 10th Revision [ICD ‑10]), derived from the database of the obligatory healthcare payer in Poland.The current analysis included all patients after AMI who were discharged …

MaleMEDLINEMyocardial InfarctionDischarged alive030204 cardiovascular system & hematologycomputer.software_genre03 medical and health sciences0302 clinical medicineOlder patientsRisk FactorsmedicineHumansIn patientcardiovascular diseasesMyocardial infarctionAgedAged 80 and overnon-ST-segment elevation myocardial infarctionDatabaseRelative survivalbusiness.industryrelative survivalMiddle Agedmedicine.diseasePatient DischargeST-segment elevation myocardial infarctionHospitalizationHeart failurepopulation-based databaseFemalePolandCardiology and Cardiovascular MedicineIndex hospitalizationbusinesscomputerlong-term outcomesKardiologia polska
researchProduct

Long-Term Clinical Outcomes According to Previous Manifestations of Atherosclerotic Disease (from the FAST-MI 2010 Registry)

2017

IF 3.398; International audience; The prognosis of patients with acute myocardial infarction (AMI) has notably improved in the past 20 years. Using the French Registry of ST-Elevation and Non-ST-elevation Myocardial Infarction (FAST-MI) 2010 registry, we investigated whether previous manifestations of atherosclerotic disease (i.e., previous MI, or a history of any form of atherosclerotic disease) are at truly increased risk compared with those in whom AMI is the first manifestation of the disease. FAST-MI 2010 is a nationwide French registry including 3,079 patients with AMI, among whom 1,062 patients had a history of cardiovascular atherosclerotic disease and 498 patients had a history of …

MaleMESH : Atherosclerosismedicine.medical_treatmentMESH : MortalityMyocardial InfarctionMESH : AgedMESH : Prospective StudiesAngiotensin-Converting Enzyme InhibitorsCoronary Artery DiseaseDiseaseMESH : Cerebrovascular Disorders0302 clinical medicineMedicineLongitudinal StudiesProspective StudiesMESH: Coronary Artery DiseaseMyocardial infarctionCoronary Artery BypassMESH: Treatment OutcomeCause of deathAged 80 and overeducation.field_of_studyMESH: Middle AgedHazard ratioMESH : Platelet Aggregation InhibitorsPrognosisMESH: Case-Control Studies3. Good healthMESH: Myocardial InfarctionMESH: Angiotensin Receptor AntagonistsMESH : Angiotensin-Converting Enzyme InhibitorsCardiology and Cardiovascular MedicineMESH: Percutaneous Coronary InterventionMESH : Case-Control Studiesmedicine.medical_specialtyMESH : Angiotensin Receptor AntagonistsMESH: Prognosis03 medical and health sciencesPercutaneous Coronary Intervention[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHumansMESH : Middle AgedMESH : Coronary Artery DiseaseMESH : Aged 80 and overMESH: Hydroxymethylglutaryl-CoA Reductase InhibitorseducationMESH: Age DistributionAgedMESH: HumansMESH: MortalityProportional hazards modelMESH: Coronary Artery BypassMESH : HumansCase-control studyMESH : Proportional Hazards Modelsmedicine.diseaseMESH : Coronary Artery BypassCase-Control StudiesMESH: FemaleMESH: RegistriesMESH : Age Distribution030204 cardiovascular system & hematologyMESH: AtherosclerosisMESH: Proportional Hazards ModelsMESH: Cause of DeathMESH: Aged 80 and overMESH : Percutaneous Coronary InterventionRisk FactorsMESH: Risk FactorsCause of DeathMESH : FemaleRegistries030212 general & internal medicineMESH: Longitudinal StudiesMESH : Longitudinal StudiesMESH: AgedMESH : PrognosisMESH: Angiotensin-Converting Enzyme InhibitorsMESH: Adrenergic beta-AntagonistsMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemMESH : Risk FactorsTreatment OutcomeMESH: Platelet Aggregation InhibitorsCardiologyFemaleMESH: Cerebrovascular DisordersFranceMESH : MaleAdrenergic beta-AntagonistsMESH : Adrenergic beta-AntagonistsPopulationMESH : Treatment OutcomeMESH: Multivariate AnalysisAngiotensin Receptor AntagonistsAge DistributionInternal medicineMortalityMESH : FranceProportional Hazards ModelsMESH : Cause of Deathbusiness.industryMESH : Hydroxymethylglutaryl-CoA Reductase InhibitorsMESH : Multivariate AnalysisPercutaneous coronary interventionAtherosclerosisMESH: MaleMESH: Prospective StudiesMESH: FranceCerebrovascular DisordersMultivariate AnalysisHydroxymethylglutaryl-CoA Reductase InhibitorsMESH : Myocardial InfarctionbusinessPlatelet Aggregation InhibitorsMESH : RegistriesThe American Journal of Cardiology
researchProduct

Smoking and FOS expression from blood leukocyte transcripts in patients with coronary artery disease.

2011

International audience; OBJECTIVE: Analysis of the leukocyte transriptome, in particular the Finkel-Biskis-Jinkins Osteosarcoma (c-Fos) gene, which has a prominent role in inflammation, provides new insights into atherosclerosis mechanisms. Although smoking is a major risk factor, the links between smoking status and coronary artery disease (CAD) remains unclear. We aimed to analyze the relationship between smoking status and c-Fos expression in circulating leukocytes of patients with CAD. METHODS: c-Fos expression was measured by RT-Q-PCR, from blood leukocytes of 239 consecutive patients after acute myocardial infarction (MI). The patients were asked about their smoking status and stratif…

MaleMESH : RNA MessengerMESH: Chi-Square DistributionMESH : LeukocytesMESH : Prospective StudiesMESH : AgedMyocardial InfarctionSmoking PreventionMESH: Risk Assessmentc-FosMESH : Coronary Angiography0302 clinical medicineMESH : Genetic MarkersProspective StudiesMESH: Coronary Artery DiseaseAged 80 and over0303 health sciencesMESH: Middle AgedGenes fosMESH: Smoking Cessation3. Good healthMESH : SmokingMESH: Myocardial InfarctionOsteosarcomaSmoking statusCardiology and Cardiovascular MedicineGenetic Markersmedicine.medical_specialtyRisk AssessmentMESH: Leukocytes03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHumansMESH : Middle AgedRNA MessengerMESH : Coronary Artery DiseaseRisk factorMESH : Aged 80 and overAgedChi-Square DistributionMESH: HumansMESH : Chi-Square DistributionMESH : Smoking CessationMESH : Humansmedicine.diseaseMESH: Coronary AngiographyLinear ModelsMESH: FemaleBlood leukocyte transcriptomeMESH : Genes fos030204 cardiovascular system & hematologyMESH: Genetic MarkersBioinformaticsCoronary AngiographyCoronary artery diseaseMESH: Linear ModelsCoronary artery diseaseMESH: Aged 80 and overRisk FactorsMESH: Risk FactorsMESH : Linear ModelsLeukocytesMESH : FemaleMESH : Risk AssessmentMESH: Agedc-FosbiologySmoking[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemMiddle AgedMESH : Risk Factors[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemCardiologyFemaleFrancemedicine.symptomInflammation MediatorsMESH: SmokingMESH : MaleMESH: Inflammation MediatorsInflammationMESH: Genes fosMESH: Multivariate AnalysisMESH : Inflammation MediatorsInternal medicinemedicineIn patientMESH : France030304 developmental biologyMESH: RNA Messengerbusiness.industryMESH : Multivariate AnalysisMESH: MaleMESH: Prospective StudiesMESH: FranceMultivariate Analysisbiology.proteinSmoking CessationMESH : Myocardial Infarctionbusiness
researchProduct

Cardiac rehabilitation and 5-year mortality after acute coronary syndromes: The 2005 French FAST-MI study.

2016

IF 2.271; International audience; Background. - Clinical studies have shown a beneficial effect of cardiac rehabilitation (CR) on mortality.Objective. - To study the effect of CR prescription at discharge on 5-year mortality in patients with acute myocardial infarction (AMI).Methods. - Participants, from the 2005 French FAST-MI hospital registry, were 2894 survivors at discharge, divided according to AMI type: ST-segment elevation myocardial infarction (STEMI; n=1523) and non-STEMI (NSTEMI; n=1371). The effect of CR prescription on mortality was analysed using a Cox proportional hazards model.Results. - At discharge, 22.1% of patients had a CR prescription. Patients referred to CR were youn…

MaleMESH: Chi-Square Distributionmedicine.medical_treatmentMESH : Acute Coronary SyndromeMyocardial InfarctionMESH : AgedMESH : Prospective StudiesCardiac rehabilitationMESH: Risk Assessment0302 clinical medicineMyocardial infarctionProspective StudiesReferral and ConsultationMESH: Treatment OutcomeRehabilitationMESH: Middle AgedGeneral MedicineMESH: Follow-Up Studies3. Good healthMESH: Myocardial InfarctionMESH : Patient DischargeCardiology and Cardiovascular Medicinemedicine.medical_specialtyAcute myocardial infarctionMortalitéRisk Assessment03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHumansMESH : Middle AgedAcute Coronary SyndromeMESH: Kaplan-Meier EstimateAgedChi-Square DistributionMESH: HumansMESH : Chi-Square DistributionProportional hazards modelMESH: Patient DischargeMESH : HumansPatient survivalMESH : Follow-Up Studiesmedicine.diseaseMESH : Proportional Hazards ModelsMESH: Acute Coronary SyndromeST-segment elevation myocardial infarctionMESH: FemaleTime FactorsMESH: RegistriesKaplan-Meier Estimate030204 cardiovascular system & hematologyMESH : Referral and ConsultationMESH: Proportional Hazards ModelsOlder patientsRisk FactorsMESH: Risk FactorsMESH : Female030212 general & internal medicineRegistriesMESH : Risk AssessmentMESH: AgedEjection fractionNon–ST-segment elevation myocardial infarctionMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemMESH : Risk FactorsPatient DischargeTreatment OutcomeFemaleFranceMESH : Time FactorsMESH : MaleMESH : Treatment OutcomeMESH: Multivariate AnalysisMESH : Kaplan-Meier EstimateMESH: Referral and ConsultationInternal medicineInfarctus du myocarde sans sus-décalage du segment STmedicineIn patientcardiovascular diseasesMedical prescriptionMortalityRéadaptation cardiaqueMESH : FranceProportional Hazards Modelsbusiness.industryInfarctus du myocarde avec sus-décalage du segment STMESH: Time FactorsMESH : Multivariate AnalysisMESH: MaleMESH: Prospective StudiesSurgeryMESH: FranceInfarctus du myocarde aiguMultivariate AnalysisMESH : Myocardial InfarctionbusinessMESH : RegistriesFollow-Up Studies
researchProduct

ST-segment elevation myocardial infarction: Management and association with prognosis during the COVID-19 pandemic in France.

2021

Systems of care have been challenged to control progression of the COVID-19 pandemic. Whether this has been associated with delayed reperfusion and worse outcomes in French patients with ST-segment elevation myocardial infarction (STEMI) is unknown.Aim: To compare the rate of STEMI admissions, treatment delays, and outcomes between the first peak of the COVID-19 pandemic in France and the equivalent period in 2019.Methods: In this nationwide French survey, data from consecutive STEMI patients from 65 centres referred for urgent revascularization between 1 March and 31 May 2020, and between 1 March and 31 May 2019, were analysed. The primary outcome was a composite of in-hospital death or no…

MaleMESH: Hyperlipidemiasmedicine.medical_treatmentMESH: ComorbidityComorbidity030204 cardiovascular system & hematologyMESH: Health Care SurveysMESH: HypertensionMESH: Procedures and Techniques Utilization0302 clinical medicinePatient AdmissionInterquartile rangeMESH: Risk FactorsRisk FactorsST segmentMESH: COVID-19030212 general & internal medicineMyocardial infarctionHospital MortalityMESH: Treatment Outcomeeducation.field_of_studyMESH: Middle AgedCardiogenic shockSmokingMESH: Patient Acceptance of Health CareGeneral MedicineMESH: Heart Rupture Post-InfarctionMiddle AgedPrognosis[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemTreatment OutcomeHypertensionCardiologyFemaleStentsFranceCardiology and Cardiovascular MedicineSCA ST+MESH: Percutaneous Coronary Interventionmedicine.medical_specialtyMESH: PandemicsMESH: SmokingMESH: Diabetes MellitusPopulationComplications mécaniquesHyperlipidemiasRevascularizationMESH: PrognosisTime-to-TreatmentSTEMI03 medical and health sciencesPercutaneous Coronary Intervention[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineLockdownmedicineDiabetes MellitusHumansMESH: SARS-CoV-2MESH: Time-to-TreatmentMESH: Hospital MortalityMESH: ST Elevation Myocardial InfarctioneducationPandemicsHeart Rupture Post-InfarctionMESH: Humansbusiness.industryMESH: Patient AdmissionSARS-CoV-2Percutaneous coronary interventionCOVID-19Patient Acceptance of Health Caremedicine.diseaseComorbidityMESH: MaleMESH: FranceMESH: Stents[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieHealth Care SurveysST Elevation Myocardial Infarction[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieMechanical complicationsbusinessMESH: FemaleProcedures and Techniques UtilizationConfinementArchives of cardiovascular diseases
researchProduct

Hospital readmission rates: signal of failure or success?

2013

AbstractHospital readmission rates are increasingly used as signals of hospital performance and a basis for hospital reimbursement. However, their interpretation may be complicated by differential patient survival rates. If patient characteristics are not perfectly observable and hospitals differ in their mortality rates, then hospitals with low mortality rates are likely to have a larger share of un-observably sicker patients at risk of a readmission. Their performance on readmissions will then be underestimated. We examine hospitals’ performance relaxing the assumption of independence between mortality and readmissions implicitly adopted in many empirical applications. We use data from th…

MaleMORTALITY-RATESEconomicsIMPACTSocial SciencesHospital performanceC50Business & EconomicsReadmission ratesmedia_commonAged 80 and overHip fractureOUTCOMESI18Mortality rateHealth PolicyHEALTH CARE SCIENCES & SERVICESHospitalsSurvival RateEngland1117 Public Health And Health ServicesMortality ratesFemaleMedical emergencyHEALTHLife Sciences & BiomedicineSample selectionmedicine.medical_specialtyACUTE MYOCARDIAL-INFARCTIONmedia_common.quotation_subjectBivariate analysisPatient ReadmissionReadmission ratemedicineQUALITYHumansSurvival rate1402 Applied EconomicsSelection (genetic algorithm)AgedQuality of Health CareSelection biasHospital readmissionSAMPLE SELECTIONScience & TechnologyModels Statisticalbusiness.industryHip FracturesPublic Health Environmental and Occupational HealthHIP FRACTUREHEALTH POLICY & SERVICESmedicine.diseaseMortality rateMODELEmergency medicinebusinessRACOSTS
researchProduct

Zofenopril and ramipril in patients with left ventricular systolic dysfunction after acute myocardial infarction: A propensity analysis of the Surviv…

2016

Introduction: This was a propensity score analysis of the prospective, randomized, double-blind Survival of Myocardial Infarction Long-term Evaluation (SMILE) 4 study in which one-year treatment with zofenopril 60 mg plus acetylsalicylic acid (ASA) 100 mg gave superior results compared to ramipril 10 mg plus ASA in terms of death or hospitalization for cardiovascular causes in patients with acute myocardial infarction (AMI) complicated by left ventricular dysfunction (LVD). Materials and methods: A total of 716 patients of the intention-to-treat population were divided into homogeneous propensity quintiles (Q) using a logistic regression model (QI: best risk profile; QV: worst risk profile)…

MaleMedicine (General)Time FactorsCaptoprilIntention to Treat AnalysiLeftMyocardial Infarction030204 cardiovascular system & hematologychemistry.chemical_compoundVentricular Dysfunction Left0302 clinical medicineEndocrinologyRamiprilPropensity analysisAcetylsalicylic acid; Acute myocardial infarction; Angiotensin-converting enzyme inhibitors; Left ventricular dysfunction; Propensity analysis; Captopril; Demography; Drug Therapy Combination; Endpoint Determination; Female; Hospitalization; Humans; Intention to Treat Analysis; Male; Middle Aged; Myocardial Infarction; Ramipril; Survival Analysis; Time Factors; Ventricular Dysfunction Left; Propensity Score; Internal Medicine; EndocrinologyVentricular DysfunctionMedicine030212 general & internal medicineMyocardial infarctioneducation.field_of_studyLeft ventricular dysfunctionElectrocardiography in myocardial infarctionMiddle AgedZofenoprilIntention to Treat AnalysisHospitalizationCombinationCardiologyOriginal ArticleDrug Therapy CombinationFemaleSurvival AnalysiPropensity analysimedicine.drugHumanRamiprilmedicine.medical_specialtyTime FactorEndpoint DeterminationPopulationAcute myocardial infarction03 medical and health sciencesR5-920Drug TherapyInternal medicineAngiotensin-converting enzyme inhibitorsAcetylsalicylic acidInternal MedicineHumanseducationPropensity ScoreDemographybusiness.industryOdds ratiomedicine.diseaseSurvival AnalysisConfidence intervalchemistryAngiotensin-converting enzyme inhibitorPropensity score matchingbusiness
researchProduct

Neuroprotection and glutamate attenuation by acetylsalicylic acid in temporary but not in permanent cerebral ischemia.

2007

To assess the effects of acetylsalicylic acid (ASA) on glutamate and interleukin-6 (IL-6) release in the striatum of rats suffering from cerebral ischemia, we used the microdialysis technique with probes implanted 2 h prior to stroke onset. A total of 36 rats were randomly assigned to either temporary (90 min, n = 18) or permanent (n = 18) middle cerebral artery occlusion (MCAO). Animals received either a bolus of 40 mg/kg ASA or saline as control 30 min after stroke onset. Permanent MCAO led to large infarct volumes with no differences between treatment with ASA (239.8 ± 4.1 mm3) and saline (230.1 ± 3.9 mm3, p = 0.15). In contrast, ASA therapy in temporary ischemia (87.2 ± 6.2 mm3) reduced…

MaleMicrodialysisTime Factorsmedicine.medical_treatmentIschemiaGlutamic AcidEnzyme-Linked Immunosorbent AssayNeuroprotectionBrain IschemiaBrain ischemiaBolus (medicine)Developmental NeurosciencemedicineAnimalscardiovascular diseasesRats WistarSalinePeroxidaseAnalysis of VarianceAspirinbusiness.industryInterleukin-6PenumbraGlutamate receptorCerebral Infarctionmedicine.diseaseRatsDisease Models AnimalNeuroprotective AgentsNeurologyGene Expression RegulationIschemic Attack TransientAnesthesiabusinessProto-Oncogene Proteins c-fosExperimental neurology
researchProduct